Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Locally Advanced Prostate Cancer: early-phase trial registry

2 of 2 indexed Locally Advanced Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Locally Advanced Prostate Cancer: 2 US clinical trials tracked, 2 recruiting.

Locally Advanced Prostate Cancer is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Angela Y. Jia, MD PhD, running 1 of these trials.

Enrollment posture brief

Registry condition locally-advanced-prostate-cancer

OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Locally Advanced Prostat (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Locally Advanced Prostate Cancer

Locally Advanced Prostate Cancer lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Locally Advanced Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Locally Advanced Prostate Cancer is recruiting above its size-band peers.

    2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 12

Phase Distribution

PhaseTrial count
Phase 1 2

Top Sponsors

Named interventions

Most-linked intervention names on Locally Advanced Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Relugolix and Enzalutamide Drug
1 trials
5-fraction Stereotactic Body Radiation Therapy (SBRT) Radiation
1 trials
Lu-PSMA-617 Drug
1 trials

US sites by state

Facility locations filed on Locally Advanced Prostate Cancer trials. A trial with sites in several states counts in each.

Oklahoma 1 trials
Ohio 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Locally Advanced Prostate Cancer page

2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Locally Advanced Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Angela Y. Jia, MD PhD sponsors the most Locally Advanced Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Angela Y. Jia, MD PhD's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Locally Advanced Prostate Cancer condition card totals 2 registered trials; most-linked intervention Relugolix and Enzalutamide; top US site state Oklahoma. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.